Chromocell Issues Letter to Stockholders from Chief Executive Officer
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer...
Clinical Trial
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™...
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
Clearmind Medicine CEO Issues Letter to Shareholders
Vancouver, Canada, April 09, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq:CMND), (FSE: CWY0) (“Clearmind” or the “company”), a clinical-stage...
Mainz Biomed Reports Full Year 2023 Financial Results
ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of...
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that...
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Enrollment to continue to the end of April to accommodate strong patient and site interestNAARDEN, the Netherlands and MIAMI, April...
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
First-in-class multimodal immunotherapy candidate, for induction of tertiary lymphoid structures, being developed as a novel therapeutic strategy for solid tumors...
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted...
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of...
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin...
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Rezdiffra Rezdiffra product image Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH...
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused,...
Red Light Holland Launches Its Largest Psilocybin Shipment to Canada with Health Canada Approved Import Permit; Debenture Offering Successfully Closed
Toronto, Ontario--(Newsfile Corp. - April 9, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light...
Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (NASDAQ:BPTS), (Euronext Growth Paris:ALBPS), ("Biophytis" or...
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2023
WINNIPEG, MB / ACCESSWIRE / April 8, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTCPINK:MCUJF), a company focused on...
Cantargia presents unique effects of nadunolimab in pancreatic cancer
LUND, SE / ACCESSWIRE / April 8, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented new...
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq’s Bid Price Requirement
Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrheaSAN FRANCISCO,...
DEA Faces Marijuana Legal Scrutiny: Hindering MMJ BioPharma Cultivation Marijuana Supply For Clinical Trials
Exposing the Secret: Federal Marijuana Production Remains NonexistentThe DEA Games Continue To Delay Legitimate Marijuana Clinical Trials and ResearchWASHINGTON, DC...
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...